- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
February 8th, 2005
Flamel Technologies announced today that it has posted a summary of Phase IIa data conducted on Flamel's long-acting insulin, Basulin®, on its website.
"We are pleased with the results of the Phase IIa obtained on thirty (30) Type I diabetic patients. This study confirms our strong expectations for Basulin® because Medusa®, our nano-particulate system, is the only one capable to delivery human insulin with this level of efficacy," said Dr. Gerard Soula.
|Related News Press|
Molecular trick alters rules of attraction for non-magnetic metals August 5th, 2015
Global Carbon Nanotubes Industry 2015: Acute Market Reports August 4th, 2015
Glitter from silver lights up Alzheimer's dark secrets August 25th, 2015
Cervical cancer detection goes portable August 25th, 2015
Antibacterial Nanocomposite Prevents Transmission of Infectious Diseases August 24th, 2015
Successful boron-doping of graphene nanoribbon August 27th, 2015
Nanolab Technologies LEAPS Forward with High-Performance Analysis Services to the World: Nanolab Orders Advanced Local Electrode Atom Probe (LEAP®) Microscope from CAMECA Unit of AMETEK Materials Analysis Division August 27th, 2015